Table 1 Risk of amputation, PAD and DF events in patients with SGLT2i treatment
From: Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysis
Subgroup | No. of participants (SGLT2i/control) | OR | 95% CI | P value | I2 (%) |
|---|---|---|---|---|---|
Risk of amputation by SGLT2i subtypes | |||||
In total* | 40,765/33,406 | 1.21 | 1.06, 1.37 | 0.004 | 4 |
Canagliflozin* | 7990/6541 | 1.60 | 1.04, 2.46 | 0.03 | 67 |
Dapagliflozin | 13,236/13,234 | 1.05 | 0.85, 1.30 | 0.66 | 0 |
Empagliflozin | 7101/4463 | 1.07 | 0.76, 1.49 | 0.71 | 0 |
Ertugliflozin | 5493/2745 | 1.24 | 0.87, 1.76 | 0.23 | NA |
Sotagliflozin | 6945/6423 | 1.08 | 0.68, 1.70 | 0.75 | 0 |
Risk of amputation by study types | |||||
CVOT and ROT* | 39,020/32,465 | 1.20 | 1.06, 1.37 | 0.005 | 30 |
Efficacy and safety evaluation | 1745/941 | 1.80 | 0.36, 8.95 | 0.47 | 0 |
Risk of amputation by population | |||||
DM only* | 34,715/27,194 | 1.24 | 1.08, 1.42 | 0.002 | 15 |
Including patients without DM | 6380/6380 | 1.00 | 0.70, 1.43 | 1.00 | 0 |
Risk of amputation by control types | |||||
Active agent | 551/267 | 1.46 | 0.06, 35.90 | 0.82 | NA |
Placebo* | 40,214/33,139 | 1.21 | 1.06, 1.37 | 0.004 | 11 |
Risk of amputation by study duration (weeks) | |||||
< 26 | 145/148 | 3.08 | 0.12, 76.30 | 0.49 | NA |
26–52 | 2205/1404 | 2.34 | 0.58, 9.52 | 0.23 | 0 |
> 52* | 38,415/31,854 | 1.20 | 1.05, 1.36 | 0.006 | 31 |
Risk of PAD by SGLT2i subtypes | |||||
In total* | 36,701/28,676 | 1.21 | 1.03, 1.42 | 0.02 | 0 |
Canagliflozin* | 10,465/7965 | 1.53 | 1.14, 2.05 | 0.005 | 0 |
Dapagliflozin | 15,821/14,655 | 1.02 | 0.81, 1.29 | 0.85 | 0 |
Empagliflozin | 8111/4560 | 1.25 | 0.88, 1.78 | 0.21 | 0 |
Ertugliflozin | 1605/793 | 1.49 | 0.30, 7.42 | 0.62 | 0 |
Sotagliflozin | 699/703 | 0.33 | 0.01, 8.23 | 0.50 | NA |
Risk of PAD by study types | |||||
CVOT and ROT* | 25,768/21,960 | 1.24 | 1.05, 1.46 | 0.01 | 6 |
Efficacy and safety evaluation | 10,933/6716 | 0.94 | 0.54, 1.63 | 0.82 | 0 |
Risk of PAD by population | |||||
DM only* | 32,184/24,159 | 1.22 | 1.03, 1.45 | 0.02 | 0 |
Including patients without DM | 4517/4517 | 1.10 | 0.67, 1.79 | 0.71 | 0 |
Risk of PAD by control types | |||||
Active agent | 3847/2611 | 1.00 | 0.33, 3.06 | 1.00 | 0 |
Placebo* | 32,854/26065 | 1.21 | 1.03, 1.43 | 0.02 | 0 |
Risk of PAD by study duration (weeks) | |||||
< 26 | 5114/3162 | 0.90 | 0.43, 1.89 | 0.78 | 0 |
26–52 | 2855/1717 | 1.62 | 0.48, 5.52 | 0.44 | 0 |
> 52* | 28,632/23,797 | 1.22 | 1.03, 1.44 | 0.02 | 0 |
Risk of DF by SGLT2i subtypes | |||||
In total | 32,043/25558 | 1.23 | 0.93, 1.63 | 0.15 | 0 |
Canagliflozin | 9137/7113 | 1.55 | 0.94, 2.54 | 0.09 | 0 |
Dapagliflozin | 14,586/13,806 | 1.20 | 0.79, 1.82 | 0.40 | 0 |
Empagliflozin | 7127/4055 | 0.89 | 0.48, 1.65 | 0.71 | 0 |
Ertugliflozin | 1193/584 | 1.48 | 0.15, 14.23 | 0.74 | 0 |
Risk of DF by study types | |||||
CVOT and ROT | 25,768/21,960 | 1.23 | 0.91, 1.66 | 0.17 | 0 |
Efficacy and safety evaluation | 6275/3598 | 1.23 | 0.53, 2.84 | 0.63 | 0 |
Risk of DF by population | |||||
DM only | 27,526/21,041 | 1.27 | 0.95, 1.71 | 0.11 | 0 |
Including patients without DM | 4517/4517 | 0.89 | 0.34, 2.31 | 0.81 | 0 |
Risk of DF by control types | |||||
Active agent | 4164/2459 | 1.53 | 0.44, 5.33 | 0.50 | 0 |
Placebo | 27,879/23,099 | 1.22 | 0.91, 1.63 | 0.18 | 0 |
Risk of DF by study duration (weeks) | |||||
< 26 | 1183/562 | 1.45 | 0.23, 9.22 | 0.69 | 0 |
26–52 | 3029/1606 | 1.45 | 0.42, 4.93 | 0.56 | 0 |
> 52 | 27,831/23,390 | 1.22 | 0.91, 1.63 | 0.19 | 0 |